Compare Regeneron Pharmaceuticals Inc (REGN) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs UBS Group AG Registered Ordinary Shares — how do they compare? Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B), while UBS Group AG Registered Ordinary Shares trades at $48.17 (market cap $142.70B). The key difference: UBS Group AG Registered Ordinary Shares is the larger of the two by market cap, and UBS Group AG Registered Ordinary Shares pays the higher dividend (2.34%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and UBS Group AG Registered Ordinary Shares for 1 Days on average.
| REGN | UBS | |
|---|---|---|
Market Cap | $76.14B | $142.70B |
Volume | 500,239 | 2,096,090 |
Sector | Health | Financials |
52-Week High | $852.03 | $55.72 |
52-Week Low | $557.73 | $36.41 |
Typical Hold Time | 107 Days | 1 Days |
Enterprise Value | $70.85B | $314.41B |
Dividend Yield | 0.51% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
